Facility Expansion Bionique completed a 32,000-square-foot expansion in Harrietstown, signaling increased capacity to scale mycoplasma testing and GMP services for cell therapies, vaccines, and biopharma products.

Strategic Partnerships Recent collaboration with Bionova Scientific for mycoplasma testing demonstrates appetite for CRO/CMO partnerships that can be extended to broader biopharma client networks.

Target Markets Core focus on cell and gene therapy products, clinical trial materials, biopharmaceuticals, master and working cell banks, raw materials and vaccines positions Bionique as a go-to partner for GMP mycoplasma testing and release testing across development stages.

Regulatory Strength Asahi Kasei acquisition and status as a cGMP compliant, FDA-registered facility provide credibility and a strong baseline for selling to global biopharma companies seeking proven, compliant testing partners.

Advanced Testing Offering real-time PCR, rapid microbiological methods, and full method development and validation enables faster release and biosafety testing, supporting clients moving from concept through commercialization.